Investigating how a specific protein affects the spread of triple-negative breast cancer.
The Role of Endothelial ACKR1 in Triple-Negative Breast Cancer Metastasis
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11101281
This study is looking at how a protein called ACKR1 helps triple-negative breast cancer spread in the body, and it aims to find new ways to stop or slow down that spread, which could help patients like you.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11101281 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a protein called ACKR1 in the spread of triple-negative breast cancer (TNBC), which is known for its aggressive nature and high rates of metastasis. The study aims to explore how ACKR1 interacts with a chemokine called CXCL2 to facilitate the movement of cancer cells from the bloodstream into other tissues. By examining these interactions in a controlled environment, researchers hope to uncover critical mechanisms that drive TNBC metastasis, potentially leading to new therapeutic strategies. Patients may benefit from insights gained about how to prevent or reduce the spread of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who are experiencing or at risk of metastasis.
Not a fit: Patients with non-triple-negative breast cancer or those who are not currently undergoing treatment for breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that inhibit the spread of triple-negative breast cancer, improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in understanding the mechanisms of cancer metastasis, suggesting that this approach could yield valuable insights.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROACH, SAMUEL — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: ROACH, SAMUEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.